Adimab has signed a pair of collaboration agreements with Celgene and Innovent Biologics. The company will work with Celgene on a multi-target discovery program, using its proprietary platform to generate therapeutic antibodies against multiple targets. The company will work with Innovent, a Chinese antibody therapeutics and manufacturing company, for the discovery, development and commercialization of an antibody-based therapeutic program. Adimab and Celgene have entered into a collaboration w...